Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Invasive mucormycosis

6

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

6

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Lanosterol 14-alpha demethylase

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2015

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hoffman-La Roche

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

5

EPA CompTox

4

NCI_THESAURUS

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIMYCOTICS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIMYCOTICS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Triazole derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Isavuconazole

60UTO373KE

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2015

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Lanosterol 14-alpha demethylase

Lanosterol 14-alpha demethylase

Conditions:

Invasive aspergillosis

Invasive mucormycosis

Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cy...

toplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

Isavuconazonium bromide dihydrobromide

MXN2HC5UUU

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2015

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Lanosterol 14-alpha demethylase

Lanosterol 14-alpha demethylase

Conditions:

Invasive aspergillosis

Invasive mucormycosis

Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cy...

toplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

Isavuconazonium Sulfate

31Q44514JV

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2015

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Lanosterol 14-alpha demethylase

Lanosterol 14-alpha demethylase

Conditions:

Invasive aspergillosis

Invasive mucormycosis

Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cy...

toplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

ISAVUCONAZONIUM CHLORIDE DIHYDROCHLORIDE

180NBU028B

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2015

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Lanosterol 14-alpha demethylase

Lanosterol 14-alpha demethylase

Conditions:

Invasive aspergillosis

Invasive mucormycosis

Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cy...

toplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

Isavuconazonium

VH2L779W8Q

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2015

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Lanosterol 14-alpha demethylase

Lanosterol 14-alpha demethylase

Conditions:

Invasive aspergillosis

Invasive mucormycosis

Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cy...

toplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

ISAVUCONAZONIUM CHLORIDE

HZQ5R80I6Y

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 2015

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Lanosterol 14-alpha demethylase

Lanosterol 14-alpha demethylase

Conditions:

Invasive aspergillosis

Invasive mucormycosis

Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cy...

toplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1